Athymic Nude Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer NU/NU Nude AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Demonstration of Broad In Vivo Anti-Tumor Activity of ARRY-142886 (AZD6244), a Potent and Selective MEK Inhibitor Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 Fox Chase SCID Mouse (C.B.17SCID) ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors BALB/c Nude Potentiation of Platinum Antitumor Effects in Human Lung Tumor Xenografts by the Angiogenesis Inhibitor Squalamine: Effects on Tumor Neovascularization AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer CD-1 Nude Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4 H-chromenes, a novel series of anticancer agents
